Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

It looks like cannabis stocks have entered the  "meme" stock  fray, as shares of Tilray Inc (NASDAQ:TLRY) were last seen up 10.6% at $22.36.

Pot Stock's Options Pits Ignite as Reddit Traders Move In

Cantor Fitgerald upgraded Tilray to overweight. Unfortunately, it also lowered price target for TLRY stock to $22.

Analysts' Latest Move Suggests Tilray's a Buy Under $20

Tilray Inc (NASDAQ:TLRY) is trading higher Wednesday morning amid increased retail interest following the launch of a new medical cannabis brand.  What Happened: Tilray on Tuesday announced Symbios, a new medical cannabis brand it launched in order to provide a broader spectrum of formats and unique cannabinoid ratios at a better price point.

Why Is Tilray Trading Higher Today?

Tilray, Inc. (NASDAQ:TLRY) announced Tuesday the launch of a new medical brand, Symbios, as well as a new line of topical treatments under its Aphria brand. Symbios will offer a range of products including dried flower, oils and pre-rolls while Aphria's new product line is aimed specifically at patients suffering from inflammatory joint disease.

Is Tilray The Next Short Squeeze Candidate?

In the last few months, there was no news bigger than the TLRY-APHA merger. But even after the tie-up, TLRY stock is not a winner.

Tilray Stock Will Keep Disappointing With Poor Numbers and No Catalysts

AMC Entertainment

Here's how they compare in several key areas.

Better Meme Stock: AMC Entertainment or Tilray?

Tilray, Inc. (TLRY) CEO Irwin Simon Presents at Stifel 2021 Virtual Cross Sector Insight Conference (Transcript)

The company now has three medical pot lines.

Tilray Launching New Medical Marijuana Brand

BlackBerry

Bed Bath & Beyond

GameStop

Nikola

Nokia

Pennsylvania Real Estate Investment Trust

PetMed Express

Palantir Technologies

SNDL Inc.

Through creating retail investor interest on platforms like Facebook, Reddit, and Robinhood, certain companies have seen massive surges in share prices and volumes.

12 Reddit Stocks To Watch Right Now

Academy Sports and Outdoors

Clean Energy Fuels

Clover Health Investments

Wendy's

Workhorse Group

Reddit continues to be the home of meme stocks and with the recent rally, it's worth looking at what they are talking about. The post The 10 Most Talked About Stocks on Reddit Today appeared first on InvestorPlace.

The 10 Most Talked About Stocks on Reddit Today

On Tuesday, Canadian cannabis company Tilray, Inc. (NASDAQ:TLRY) (TSX:TLRY) announced the launch of a new brand dubbed Symbios. This is the inaugural brand produced by the "new" Tilray and will provide medical patients with a broader spectrum of formats and cannabinoid ratios at a fair and reasonable price.

The 'New' Tilray Launches Medical Cannabis Brand Symbios, Announces New Aphria Topicals

Canopy Growth

Are These The Top Canadian Marijuana Stocks To Invest In ? The post Best Canadian Marijuana Stocks To Buy? 2 For Your Watchlist appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Best Canadian Marijuana Stocks To Buy? 2 For Your Watchlist

NEW YORK & LEAMINGTON, Ontario--(BUSINESS WIRE)--Tilray, Inc. (“Tilray”) (NASDAQ | TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today announced the launch of Symbios, a complement to the Company's existing medical brand portfolio in Canada. This new brand was developed to provide a broader spectrum of formats and unique cannabinoid ratios at a better price point while offering medical patients a full comprehensive assortment of products, including flower,

Tilray Announces Launch of New Medical Cannabis Brand, Symbios

Tilray Inc (NASDAQ:TLRY) and Sundial Growers Inc (NASDAQ:SNDL) are trading higher Monday morning as retail traders continue to favor the pair of cannabis stocks.  What Happened: Cannabis stocks have trended higher recently as positive cannabis industry news continues to make headlines.

Why Tilray And Sundial Growers Are Trading Higher Today

Shares of medical cannabis company Tilray Inc. (NASDAQ:TLRY) on Thursday gained 3.79% after Cantor Fitzgerald analyst Pablo Zuanic upgraded the stock to a buy rating. TLRY stock is now up 18.30% this month and is still far from Zuanic's lower price target of $22.00 per share.

Tilray was double upgraded at Cantor Fitzgerald: should you buy TLRY now?

The bigger the better, it seems, in the marijuana business.

Why Sundial Growers and Tilray Are Flying High This Week

Aurora Cannabis

Applied DNA Sciences

Arena Pharmaceuticals

HEXO Corp

FSD Pharma

Neptune Wellness Solutions Inc.

OrganiGram Holdings Inc.

cbdMD Inc

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.

Breaking Down a Busy Week of Weed Stocks

The stock prices of Sundial Growers Inc (NASDAQ: SNDL) and Tilray Inc (NASDAQ: TLRY) increased yesterday by 14.16% and 3.79%, respectively. This is why it happened.

SNDL And TLRY Stock Prices Increased Yesterday: Explanation

Aphria

Cantor Fitzgerald assigned Tilray Inc. an overweight rating this week and said the new company -- it recently closed its merger with Aphria Inc. -- is alone among Canadian licensed producers with domestic scale and a credible overseas platform. Analyst Pablo Zuanic assigned the stock a $22 price target that is down from $30.25 before the merger, but about 11.5% above its current trading level.

Tilray rated overweight at Cantor after Aphria merger closes

Behind the underdogs trying to achieve financial freedom are masterminds that match the best of Wall Street.

What's Behind the Recent Meteoric Rise in Meme Stocks?

CrowdStrike

DocuSign

Workhorse, Docusign, Crowdstrike and Tilray were our top stock trades for Friday. Now, let's look at how the charts are setting up.

4 Top Stock Trades for Friday: WKHS, DOCU, CRWD, TLRY

Cannabis stocks are on the rebound today. Congress is looking at legalization, Amazon backs it, and Reddit is all-in once again.

Cannabis Stocks: How Reddit and Amazon Are Boosting TLRY, SNDL Stocks Today

An analyst upgrade is boosting the pot titan's shares.

Why Tilray Stock Is Heading Higher Today

Institutions have increased their short position on Tilray Inc (NASDAQ:TLRY) by over 12 million in the last month alone and it looks as though they're about to regret it. Of Tilray's 426.82 million float, 34.81 million shares are held short as of May 14 versus the only 22.25 that were held short as of April 14.

Are Tilray Shorts About To Get Wrecked?

The two Canadian cannabis giants Tilray Inc. (NASDAQ: TLRY) and Aphria Inc. (NASDAQ: APHA) completed their merger in early May after months of negotiations, resulting in the world's largest cannabis company as measured by revenue. The new combined company kept the Tilray name and continues to trade on Nasdaq Global Select Exchange under the ticker TLRY.

Cantor Lowers Price Target On Tilray's Stock In Anticipation Of Quarterly Earnings

News for Tilray Brands Stock (TLRY)